文献速递神经免疫认知障碍与痴呆

多发性硬化患者的癌症风险:一项为期10年的全国性回顾性队列研究

Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
PubMed 文献 · Neurology · 2024-10-09

这项为期10年(2012-2021年)的法国全国回顾性匹配队列研究,比较了14,0649例多发性硬化(MS)患者与56,2596例匹配对照者首次发生癌症的风险。MS患者总体癌症风险轻度升高(HR 1.06,95%CI 1.03-1.08),女性尤为明显(HR 1.08,95%CI 1.05-1.11);风险因癌症类型和年龄而异,55岁以下升高(HR 1.20,95%CI 1.15-1.24),65岁及以上降低(HR 0.89,95%CI 0.85-0.94)。MS患者参加全部三项国家癌症筛查项目的比例均低于对照者。

要点

  • MS患者总体癌症风险轻度升高(HR 1.06),女性更明显(HR 1.08)。
  • 膀胱癌(HR 1.71)、脑癌(HR 1.68)、宫颈癌(HR 1.24)风险在MS患者中升高。
  • 前列腺癌(HR 0.80)、乳腺癌(HR 0.91)、结直肠癌(HR 0.90)风险在MS患者中降低。

核心结论

  • MS患者癌症风险轻度升高, particularly for urogenital cancers, possibly due to surveillance bias.
  • 风险随年龄波动, possibly due to varying generational screening practices and risk factors.

研究设计与样本

  • 这项为期10年(2012-2021年)的全国性回顾性匹配队列研究使用了法国国家行政医疗保健数据库(覆盖99%的法国人口)数据,以确定首次发生癌症的时间。
  • MS患者通过长期疾病(LTD)状态、住院记录和MS特异性药物报销记录识别;对照人群按年龄、性别、居住地、保险计划和队列进入日期以4:1比例匹配;纳入前3年内无癌症史的参与者。
  • 癌症患者通过LTD状态、住院、化疗、放疗或前列腺癌特异性药物报销记录识别。
  • 总体和癌症部位特异性首次癌症风险比(HR)通过Fine and Gray模型获得,并报告按年龄和性别分层的估计值。
  • 比较两组参加三项国家癌症筛查项目(乳腺癌、结直肠癌和宫颈癌)的情况。

主要发现

  • 在140,649例MS患者中,癌症发病率为799/100,000人年(n=8,368);在562,596例匹配对照者中为736/100,000人年(n=31,796)(70.8%为女性;随访:7.6±3.2年)。
  • MS患者总体风险轻度升高(HR 1.06,95%CI 1.03-1.08),女性中更明显(HR 1.08,95%CI 1.05-1.11)。
  • MS患者中前列腺癌(HR 0.80,95%CI 0.73-0.88)、乳腺癌(HR 0.91,95%CI 0.86-0.95)和结直肠癌(HR 0.90,95%CI 0.84-0.97)风险较低,膀胱癌(HR 1.71,95%CI 1.54-1.89)、脑癌(HR 1.68,95%CI 1.42-1.98)和宫颈癌(HR 1.24,95%CI 1.12-1.38)风险较高。
  • 55岁以下MS患者癌症风险较高(HR 1.20,95%CI 1.15-1.24),65岁及以上MS患者风险降低(HR 0.89,95%CI 0.85-0.94),该趋势见于所有癌症部位。
  • 参加所有癌症筛查项目的MS患者均少于对照者,在65岁及以上人群中差异尤为明显。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Previous literature has been diverging on cancer risk in people with multiple sclerosis (PwMS). Therefore, this study compared the risk of cancer in PwMS and a matched sample from the French general population. METHODS: This 10-year nationwide retrospective matched cohort study (2012-2021) used data from the national French administrative health care database (99% coverage of the French population) to determine the time to the first incident cancer. PwMS were identified using their long-term disease (LTD) status, hospitalizations, and multiple sclerosis (MS)-specific drug reimbursements. The control population was matched 4:1 on age, sex, residence, insurance scheme, and cohort entry date. Participants were included if they had no history of cancer in the 3 years before inclusion. Patients with cancer were identified through LTD status, hospitalizations, chemotherapy, radiotherapy, or prostate cancer-specific drug reimbursements. Overall and cancer location-specific hazard ratios (HRs) for the first incident cancer were obtained from Fine and Gray models, and age- and sex-stratified estimates were reported. Participation in cancer screening through the 3 national programs (breast, colorectal, and cervical) were compared between groups. RESULTS: Cancer incidence was 799 per 100,000 person-years (PYs) (n = 8,368) among the 140,649 PwMS and 736 per 100,000 PYs (n = 31,796) among the 562,596 matched controls (70.8% of women; follow-up: 7.6 ± 3.2 years). A small overall risk increase was observed for PwMS (HR 1.06, 95% CI 1.03-1.08), mostly in women (HR 1.08, 95% CI 1.05-1.11). Risk varied by cancer types and was lower for prostate (HR 0.80, 95% CI 0.73-0.88), breast (HR 0.91, 95% CI 0.86-0.95), and colorectal (HR 0.90, 95% CI 0.84-0.97) cancer and higher for bladder (HR 1.71, 95% CI 1.54-1.89), brain (HR 1.68, 95% CI 1.42-1.98), and cervical (HR 1.24, 95% CI 1.12-1.38) cancer in PwMS. Cancer risk was higher in PwMS younger than 55 years (HR 1.20, 95% CI 1.15-1.24) but decreased in PwMS aged 65 years and older (HR 0.89, 95% CI 0.85-0.94). This trend was found in all cancer locations. There were fewer PwMS getting screened than controls (all programs), with a particularly pronounced difference among those aged 65 years and older. DISCUSSION: Cancer risk was slightly increased in PwMS, particularly for urogenital cancers, possibly due to surveillance bias. Risk fluctuated depending on age, perhaps due to varying generational screening practices (i.e., diagnosis neglect in the older PwMS) and risk factors.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Pierret C, Mulliez A, Le Bihan-Benjamin C, et al. Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study. Neurology. 2024. PMID: 39383482. doi:10.1212/WNL.0000000000209885

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。